查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571747

製药 CRO 市场规模、份额和趋势分析报告：按类型、分子类型、服务、治疗领域、地区和细分市场进行预测，2024-2030 年

Pharmaceutical CRO Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical), By Molecule Type (Small Molecules, Large Molecules), By Services, By Therapeutic Areas, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

製药 CRO 市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球医药CRO市场规模预计将达到629.9亿美元。

由于外包趋势的上升和研发费用的上升，预计市场在预测期内将呈现 7.32% 的复合年增长率。

製药 CRO 以合约形式向各製药公司提供外包服务。製药公司外包的增加、新药研发投资的增加、製药业的扩张以及帮助 CRO 减少营运和资本支出是预计在预测期内推动市场成长的主要因素之一。

此外，对 CRO 需求的成长归因于对药物开发、产品维护和相关服务改进的需求不断增长，预计这将推动未来几年的市场成长。此外，主要市场参与者的存在和全球正在进行的临床试验预计将推动市场成长。例如，根据美国国家医学图书馆的数据，目前全球约有 83,230 项临床试验正在开放和招募中。同样，药物开发活动的增加、技术创新和收购等策略性倡议、製药公司的存在不断增加以及对製药 CRO 创新服务的需求激增是推动市场成长的主要因素。

此外，扩大与新药开发相关的技术创新以及增加生技药品的研发预计将对市场产生正面影响。目前，製药公司越来越多地获得 CRO 提供的新的高度专业化的专业知识和技术，以进行各种小分子和大分子的创新。此外，由于 CRO 支持早期检测和临床前测试，大多数製药 CRO 对小分子候选药物的开发有很高的需求。例如，2023年3月，Crown Biosciences & JSR Lifesciences宣布在新加坡设立新基地。该中心将为参与临床前和转化肿瘤药物发现和开发的公司提供支援。

製药 CRO 市场报告亮点

  • 由于药物开发场景的变化以及需要先进的能力来支持製药公司推进药品製造，临床部门在 2023 年以 75.85% 的销售份额占据市场主导地位。此外，成本效益和 CRO 数量的增加对市场成长有正面影响。
  • 由于标靶治疗潜力不断增长、个人化医疗需求不断增加以及製药公司对小分子的兴趣增加，小分子领域将在 2023 年占据市场主导地位。此外，小分子药物管道的扩张预计将为CRO提供服务创造机会。
  • 按服务划分，临床监测占最大市场占有率，2023年为20.15%。这是由于越来越多地采用临床试验管理，其中包括监管要求的监控以及从方案开拓到资料分析的一切，使其成为广泛临床试验的可行选择。
  • 以治疗领域来看，肿瘤治疗占最大市场占有率，2023年将达30.46%。该行业受到癌症发病率上升、人口老化和对药品的强劲需求的推动，从而使其在该行业占据主导地位。
  • 亚太地区在2023年占据全球市场的主导地位，销售额份额为45.60%。该地区的高市场份额归因于活跃在中国和日本等国家的 CRO 的增加。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 製药 CRO 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/补充市场展望。
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 医药CRO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章医药CRO市场：类型估计与趋势分析

  • 细分仪表板
  • 全球医药CRO市场类型波动分析
  • 2018-2030年全球製药CRO市场规模及趋势分析（按类型）
  • 药物发现
  • 临床前
  • 临床

第五章 医药CRO市场：分子类型估算及趋势分析

  • 细分仪表板
  • 全球医药CRO市场分子类型波动分析
  • 2018-2030年全球製药CRO市场规模及趋势分析（依分子型态）
  • 低分子
  • 大分子

第六章医药CRO市场：服务评估与趋势分析

  • 细分仪表板
  • 全球医药CRO市场服务波动分析
  • 2018年至2030年全球製药CRO市场规模及趋势分析（依服务）
  • 计划管理/临床供应管理
  • 资料管理
  • 监管/医疗
  • 医学写作
  • 临床监测
  • 品管/保证
  • 生物统计学
  • 支付给调查员
  • 实验室
  • 病人和设施招募
  • 科技
  • 其他的

第七章 医药CRO市场：治疗领域预估及趋势分析

  • 细分仪表板
  • 全球医药CRO市场治疗领域波动分析
  • 2018年至2030年全球製药CRO市场规模及趋势分析（依治疗领域）
  • 肿瘤学
  • 中枢神经系统疾病
  • 感染疾病
  • 免疫疾病
  • 心血管疾病
  • 呼吸系统疾病
  • 糖尿病
  • 眼科
  • 疼痛管理
  • 其他的

第八章医药CRO市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 2018-2030年北美市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 2018-2030 年亚太市场估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018年至2030年中东和非洲市场估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 公司/竞争对手分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/上市公司
    • Parexel International（MA）Corporation.
    • ICON plc
    • Laboratory Corporation of America Holdings
    • Thermo Fisher Scientific Inc.
    • Medpace
    • IQVIA
    • CTI Clinical Trial &Consulting
    • WuXi AppTec
    • Veeda Clinical Research
Product Code: GVR-4-68040-470-0

Pharmaceutical CRO Market Growth & Trends:

The global pharmaceutical CRO market size is expected to reach USD 62.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to show a lucrative CAGR of 7.32% over the forecast period due to rising outsourcing trends and increasing R&D expenditure.

Pharmaceutical CROs provide outsourcing services to various pharmaceutical companies on a contract basis. Increasing outsourcing among pharmaceutical companies, growing investments in the R&D of new drugs, expansions in the pharmaceutical industry, and CRO support in reducing operational and capital expenses are some of the major factors anticipated to propel market growth in the forecast period.

Besides, increasing demand for CRO is driven by rising requirements for improved drug development, product maintenance, and related services, which is expected to drive market growth in the coming years. In addition, the substantial presence of key market players and ongoing clinical trials globally are expected to drive market growth. For instance, according to the U.S. National Library of Medicine, about 83,230 clinical trial studies are currently active and recruiting globally, which is anticipated to contribute to market growth. Likewise, increasing drug development activities, strategic initiatives such as innovation & acquisitions, the growing presence of pharmaceutical companies, and a surge in demand for pharmaceutical CRO innovative services are key factors propelling the market growth.

Furthermore, growing technological innovations pertaining to developing novel pharmaceutical drugs and rising research and development for biologics are anticipated to influence the market positively. Currently, pharmaceutical companies are increasingly bolstering their capacities in CRO's newer, highly specific expertise and technologies for the innovation of various small & large molecules. In addition, most pharmaceutical CROs have an emerging demand for small molecule drug candidates' development as CRO supports early discovery and preclinical drug development studies. For instance, in March 2023, Crown Bioscience & JSR Life Sciences Company mentioned it's a new site in Singapore, which will support the company in expanding its capacity for biotech & pharma companies. The site will help companies that engage in preclinical & translational oncology drug discovery and development.

Pharmaceutical CRO Market Report Highlights:

  • The clinical segment dominated the market with a revenue share of 75.85% in 2023 due to changing drug development scenarios and the need for sophisticated capabilities to help pharmaceutical companies advance drug manufacturing. In addition, cost-effectiveness and the increasing number of CROs are some of the key factors positively affecting market growth.
  • The small molecules segment dominated the market in 2023 owing to the increasing potential of targeted therapies, rising demand for personalized medicine, and pharmaceutical companies' growing interest in small molecules. Besides, the expanding pipeline of small molecule drugs is anticipated to create opportunities for CROs to provide services.
  • Based on service, clinical monitoring held the largest market share of 20.15% in 2023, which is attributed to the increase in the adoption of monitoring of regulatory requirements and clinical trial management, which includes protocol development to data analysis, making it a suitable option for a wide range of clinical trials.
  • In terms of therapeutic areas, the oncology segment held the largest market share of 30.46% in 2023. The segment is driven by the growing incidence of cancer, the rising aging population, and the robust demand for pharmaceuticals, contributing to its prominence in this field.
  • Asia Pacific dominated the market globally with a revenue share of 45.60% in 2023. The region's high share is due to an increased number of actively functioning CROs, especially in China and Japan, among others.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Molecule Type Segment
    • 1.2.3. Services Segment
    • 1.2.4. Therapeutic Areas Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand For Outsourcing Services
      • 3.2.1.2. Increasing Adoption of Advanced Technologies
      • 3.2.1.3. Increasing Mergers and Collaborations
      • 3.2.1.4. Increasing Demand for Outsourcing Services Across The Developing Economies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk Associated with Data Security
      • 3.2.2.2. Monitoring Issues and Lack of Standardization
  • 3.3. Pharmaceutical CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical CRO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical CRO Market Type Movement Analysis
  • 4.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Drug Discovery
    • 4.4.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Target Validation
      • 4.4.2.1. Target validation market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Lead Identification
      • 4.4.3.1. Lead identification market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Lead Optimization
      • 4.4.4.1. Lead optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Pre-Clinical
    • 4.5.1. Pre-Clinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Clinical
    • 4.6.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.2. Phase I Trial Services
      • 4.6.2.1. Phase I Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.3. Phase II Trial Services
      • 4.6.3.1. Phase II Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.4. Phase III Trial Services
      • 4.6.4.1. Phase III Trial Services market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.5. Phase IV Trial Services
      • 4.6.5.1. Phase IV Trial Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical CRO Market: Molecule Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical CRO Market Molecule Type Movement Analysis
  • 5.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Molecule Type, 2018 to 2030 (USD Million)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Large Molecules
    • 5.5.1. Large Molecules market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical CRO Market: Services Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical CRO Market Services Movement Analysis
  • 6.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Services, 2018 to 2030 (USD Million)
  • 6.4. Project Management/Clinical Supply Management
    • 6.4.1. Project Management/Clinical Supply Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Data Management
    • 6.5.1. Data Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Regulatory/Medical Affairs
    • 6.6.1. Regulatory/Medical Affairs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Medical Writing
    • 6.7.1. Medical Writing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Clinical Monitoring
    • 6.8.1. Clinical Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Quality Management/ Assurance
    • 6.9.1. Quality Management/ Assurance market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Biostatistics
    • 6.10.1. Bio-statistics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Investigator Payments
    • 6.11.1. Investigator Payments market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Laboratory
    • 6.12.1. Laboratory market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.13. Patient And Site Recruitment
    • 6.13.1. Patient And Site Recruitment market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.14. Technology
    • 6.14.1. Technology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.15. Others
    • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical CRO Market: Therapeutic Areas Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical CRO Market Therapeutic Areas Movement Analysis
  • 7.3. Global Pharmaceutical CRO Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. CNS Disorders
    • 7.5.1. CNS Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Immunological Disorders
    • 7.7.1. Immunological Disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cardiovascular Disease
    • 7.8.1. Cardiovascular Disease market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Respiratory Diseases
    • 7.9.1. Respiratory Diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Diabetes
    • 7.10.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.11. Ophthalmology
    • 7.11.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.12. Pain Management
    • 7.12.1. Pain Management market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.13. Other
    • 7.13.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Competitive scenario
      • 8.4.2.3. Regulatory Landscape
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Competitive scenario
      • 8.4.3.3. Regulatory Landscape
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Competitive scenario
      • 8.4.4.3. Regulatory Landscape
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Competitive scenario
      • 8.5.2.3. Regulatory Landscape
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Competitive scenario
      • 8.5.3.3. Regulatory Landscape
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Competitive scenario
      • 8.5.4.3. Regulatory Landscape
      • 8.5.4.4. Reimbursement Scenario
      • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Competitive scenario
      • 8.5.5.3. Regulatory Landscape
      • 8.5.5.4. Reimbursement Scenario
      • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Competitive scenario
      • 8.5.6.3. Regulatory Landscape
      • 8.5.6.4. Reimbursement Scenario
      • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Competitive scenario
      • 8.5.7.3. Regulatory Landscape
      • 8.5.7.4. Reimbursement Scenario
      • 8.5.7.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Competitive scenario
      • 8.5.8.3. Regulatory Landscape
      • 8.5.8.4. Reimbursement Scenario
      • 8.5.8.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key country dynamics
      • 8.5.9.2. Competitive scenario
      • 8.5.9.3. Regulatory Landscape
      • 8.5.9.4. Reimbursement Scenario
      • 8.5.9.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Competitive scenario
      • 8.6.2.3. Regulatory Landscape
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Competitive scenario
      • 8.6.3.3. Regulatory Landscape
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Competitive scenario
      • 8.6.4.3. Regulatory Landscape
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Competitive scenario
      • 8.6.5.3. Regulatory Landscape
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Competitive scenario
      • 8.6.6.3. Regulatory Landscape
      • 8.6.6.4. Reimbursement Scenario
      • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Competitive scenario
      • 8.6.7.3. Regulatory Landscape
      • 8.6.7.4. Reimbursement Scenario
      • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Competitive scenario
      • 8.7.2.3. Regulatory Landscape
      • 8.7.2.4. Reimbursement Scenario
      • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Competitive scenario
      • 8.7.3.3. Regulatory Landscape
      • 8.7.3.4. Reimbursement Scenario
      • 8.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Competitive scenario
      • 8.8.2.3. Regulatory Landscape
      • 8.8.2.4. Reimbursement Scenario
      • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Competitive scenario
      • 8.8.3.3. Regulatory Landscape
      • 8.8.3.4. Reimbursement Scenario
      • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Competitive scenario
      • 8.8.4.3. Regulatory Landscape
      • 8.8.4.4. Reimbursement Scenario
      • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key country dynamics
      • 8.8.5.2. Competitive scenario
      • 8.8.5.3. Regulatory Landscape
      • 8.8.5.4. Reimbursement Scenario
      • 8.8.5.5. Israel market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2023
  • 9.4. Company Profiles/Listing
    • 9.4.1. Parexel International (MA) Corporation.
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. ICON plc
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Laboratory Corporation of America Holdings
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Thermo Fisher Scientific Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Medpace
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. IQVIA
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. CTI Clinical Trial & Consulting
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. WuXi AppTec
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Veeda Clinical Research
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical CRO, by region, 2018 - 2030 (USD Million)
  • Table 8 North America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 12 U.S. Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 15 Canada Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 17 Canada Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 18 Canada Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 20 Mexico Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 21 Mexico Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 22 Mexico Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 23 Europe Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 24 Europe Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 25 Europe Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 26 Europe Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 27 Germany Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 29 Germany Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 30 Germany Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 UK Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 32 UK Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 33 UK Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 34 UK Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 35 France Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 36 France Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 37 France Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 38 France Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 39 Italy Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 40 Italy Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 41 Italy Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 42 Italy Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Spain Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 44 Spain Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 45 Spain Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 46 Spain Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 47 Denmark Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 48 Denmark Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 49 Denmark Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 50 Denmark Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 51 Norway Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 52 Norway Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 53 Norway Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 54 Norway Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 Sweden Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 56 Sweden Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 58 Sweden Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 China Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 65 China Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 66 China Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 67 China Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 68 Japan Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 69 Japan Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 70 Japan Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 71 Japan Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 72 India Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 73 India Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 74 India Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 75 India Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 South Korea Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 77 South Korea Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 78 South Korea Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 79 South Korea Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 80 Australia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 81 Australia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 82 Australia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 83 Australia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 84 Thailand Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 85 Thailand Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 86 Thailand Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 87 Thailand Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 88 Latin America Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 90 Latin America Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 91 Latin America Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 92 Latin America Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 93 Brazil Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 94 Brazil Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95 Brazil Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 96 Brazil Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 97 Argentina Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 98 Argentina Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 99 Argentina Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 100 Argentina Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa Pharmaceutical CRO, by Country, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 106 South Africa Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 107 South Africa Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 108 South Africa Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 109 South Africa Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 114 UAE Pharmaceutical CRO, by Type, 2018 - 2030 (USD Million)
  • Table 115 UAE Pharmaceutical CRO, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 116 UAE Pharmaceutical CRO, by Services, 2018 - 2030 (USD Million)
  • Table 117 UAE Pharmaceutical CRO, by Therapeutic Areas, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmaceutical CRO Market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot 1
  • Fig. 14 Segment snapshot 2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Pharmaceutical CRO Market: Type outlook key takeaways
  • Fig. 20 Pharmaceutical CRO Market: Type movement analysis
  • Fig. 21 Drug Discovery estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Target Validation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Lead Identification market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Lead Optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pre-Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Phase I Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Phase II Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Phase III Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Phase IV Trial Services market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Pharmaceutical CRO Market: Molecule Type outlook key takeaways
  • Fig. 32 Pharmaceutical CRO Market: Molecule Type movement analysis
  • Fig. 33 Small Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Large Molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Pharmaceutical CRO Market: Services outlook key takeaways
  • Fig. 36 Pharmaceutical CRO Market: Services movement analysis
  • Fig. 37 Project Management/Clinical Supply Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Data Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Regulatory/Medical Affairs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Medical Writing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Clinical Monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Quality Management/ Assurance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Bio-statistics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Investigator Payments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Laboratory market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Patient And Site Recruitment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Technology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical CRO Market: Therapeutic Areas outlook key takeaways
  • Fig. 50 Pharmaceutical CRO Market: Therapeutic Areas movement analysis
  • Fig. 51 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 CNS Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Infectious Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Immunological Disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Cardiovascular Disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Respiratory Diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Ophthalmology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Pain Management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Regional marketplace outlook, 2023 & 2030 (USD Million)
  • Fig. 62 Regional marketplace: Key takeaways
  • Fig. 63 North America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 U.S. Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Canada Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Mexico Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Europe Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 UK Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Germany Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 France Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Spain Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Italy Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Denmark Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Norway Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Sweden Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Asia Pacific Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Japan Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 China Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 India Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Australia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 South Korea Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Thailand Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Brazil Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Argentina Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 South Africa Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Saudi Arabia Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key country dynamics
  • Fig. 112 UAE Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Kuwait Pharmaceutical CRO Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Market participant categorization
  • Fig. 116 Pharmaceutical CRO Market position analysis, 2023
  • Fig. 117 Strategic framework